Regulation of Proteasome Activity by (Post-)transcriptional Mechanisms
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Intracellular protein synthesis, folding, and degradation are tightly controlled processes to ensure proper protein homeostasis. The proteasome is responsible for the degradation of the majority of intracellular proteins, which are often targeted for degradation via polyubiquitination. However, the degradation rate of proteins is also affected by the capacity of proteasomes to recognize and degrade these substrate proteins. This capacity is regulated by a variety of proteasome modulations including (1) changes in complex composition, (2) post-translational modifications, and (3) altered transcription of proteasomal subunits and activators. Various diseases are linked to proteasome modulation and altered proteasome function. A better understanding of these modulations may offer new perspectives for therapeutic intervention. Here we present an overview of these three proteasome modulating mechanisms to give better insight into the diversity of proteasomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lysine acetylation targets protein complexes and co-regulates major cellular functions
Choudhary, C., Kumar, C., Gnad, F., Nielsen, M. L., Rehman, M., Walther, T. C., Olsen, J. V., & Mann, M. (2009) · Science · doi:10.1126/science.1175371 · Cited by 4,040
Rock, K. L., Gramm, C., Rothstein, L., Clark, K., Stein, R., Dick, L., Hwang, D., & Goldberg, A. L. (1994) · Cell · doi:10.1016/s0092-8674(94)90462-6 · Cited by 2,524
Kobayashi, A., Kang, M.-I., Okawa, H., Ohtsuji, M., Zenke, Y., Chiba, T., Igarashi, K., & Yamamoto, M. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.16.7130-7139.2004 · Cited by 2,224
Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution
Taguchi, K., Motohashi, H., & Yamamoto, M. (2011) · Genes to Cells · doi:10.1111/j.1365-2443.2010.01473.x · Cited by 1,478
Liu, B., & Hong, J.-S. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.035048 · Cited by 1,095
Muscle wasting in disease: molecular mechanisms and promising therapies
Cohen, S., Nathan, J. A., & Goldberg, A. L. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4467 · Cited by 1,089
The logic of the 26S proteasome.
Collins, G. A., & Goldberg, A. L. (2017) · Cell · doi:10.1016/j.cell.2017.04.023 · Cited by 933 · cited 1×
“After substrate binding to the proteasome, the 19S regulatory particle deubiquitinates, translocates and unfolds the substrate protein in an ATPdependent manner, so that it can be degraded by the 20S core (Navon and Goldberg, 2001; Liu C. W. et al., 2006; Liu and Jacobson, 2013; Collins and Goldberg, 2017).”
BackgroundImpaired Proteasome Function in Alzheimer's Disease
Keller, J. N., Hanni, K. B., & Markesbery, W. R. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0750436.x · Cited by 848
Oxidative stress and apoptosis: Impact on cancer therapy
Ozben, T. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20874 · Cited by 751 · cited 1×
“Since antitumor chemotherapy generally causes oxidative stress in the nucleus, and subsequently DNA damage, polyADPribosylation of the nuclear 20S proteasome might be an adaptive response, and may be partly responsible for the development of long-term resistance to many of these drugs (Ozben, 2007).”
BackgroundComplete subunit architecture of the proteasome regulatory particle
Lander, G. C., Estrin, E., Matyskiela, M. E., Bashore, C., Nogales, E., & Martin, A. (2012) · Nature · doi:10.1038/nature10774 · Cited by 608 · cited 1×
“The 19S regulatory particle contains six regulatory tripleATPase particles (RPT1–6) forming the base of the cap and 13 regulatory non-ATPase particles (RPN1–3, RPN5–13, and RPN15), which constitute the so-called lid (Figure 1) (Lander et al., 2012; Schweitzer et al., 2016).”
BackgroundRadhakrishnan, S. K., Lee, C. S., Young, P., Beskow, A., Chan, J. Y., & Deshaies, R. J. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.02.029 · Cited by 526
Smith, D. M., Chang, S.-C., Park, S., Finley, D., Cheng, Y., & Goldberg, A. L. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.06.033 · Cited by 521 · cited 1×
“Gate opening is particular induced by the C-termini of RPT2 and RPT5 through binding between the 20S α-subunits (Smith et al., 2007).”
BackgroundMyeku, N., Clelland, C. L., Emrani, S., Kukushkin, N. V., Yu, W. H., Goldberg, A. L., & Duff, K. E. (2016) · Nature Medicine · doi:10.1038/nm.4011 · Cited by 446
A mechanism of ubiquitin-independent proteasomal degradation of the tumor suppressors p53 and p73
Asher, G., Tsvetkov, P., Kahana, C., & Shaul, Y. (2005) · Genes & Development · doi:10.1101/gad.319905 · Cited by 367
Acetylation-Mediated Proteasomal Degradation of Core Histones during DNA Repair and Spermatogenesis
Qian, M.-X., Pang, Y., Liu, C. H., Haratake, K., Du, B.-Y., Ji, D.-Y., Wang, G.-F., Zhu, Q.-Q., Song, W., Yu, Y., et al. (2013) · Cell · doi:10.1016/j.cell.2013.04.032 · Cited by 330 · cited 3×
“Finally, cell-type specific proteasome subpopulations have also been identified: thymoproteasomes (β5t) and spermatoproteasomes (α4s) which vary in catalytic activity or preference for specific PAs, respectively (Murata et al., 2007; Florea et al., 2010; Qian et al., 2013; Kniepert and Groettrup, 2014).”
BackgroundProteasomal degradation of tau protein
David, D. C., Layfield, R., Serpell, L., Narain, Y., Goedert, M., & Spillantini, M. G. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01137.x · Cited by 327 · cited 1×
“, 2005) and proteins associated with neurodegenerative diseases such as α-synuclein [Parkinson’s Disease (PD)] and tau [Alzheimer’s disease (AD)] (David et al., 2002; Liu et al., 2003).”
BackgroundAutophosphorylated CaMKIIα Acts as a Scaffold to Recruit Proteasomes to Dendritic Spines
Bingol, B., Wang, C.-F., Arnott, D., Cheng, D., Peng, J., & Sheng, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.024 · Cited by 268
Mass Spectrometric Characterization of the Affinity-Purified Human 26S Proteasome Complex
Wang, X., Chen, C.-F., Baker, P. R., Chen, P.-L., Kaiser, P., & Huang, L. (2007) · Biochemistry · doi:10.1021/bi061994u · Cited by 260
Regulation of the proteasome by neuronal activity and calcium/calmodulin-dependent protein kinase II
Djakovic, S. N., Schwarz, L. A., Barylko, B., DeMartino, G. N., & Patrick, G. N. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.021956 · Cited by 236
Nuclear erythroid factor 2-mediated proteasome activation delays senescence in human fibroblasts
Kapeta, S., Chondrogianni, N., & Gonos, E. S. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.031575 · Cited by 234
Site-specific proteasome phosphorylation controls cell proliferation and tumorigenesis.
Guo, X., Wang, X., Wang, Z., Banerjee, S., Yang, J., Huang, L., & Dixon, J. E. (2016) · Nature Cell Biology · doi:10.1038/ncb3289 · Cited by 169
VerPlank, J. J. S., Lokireddy, S., Zhao, J., & Goldberg, A. L. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1809254116 · Cited by 122
Phosphorylation of Rpt6 regulates synaptic strength in hippocampal neurons
Djakovic, S. N., Marquez-Lona, E. M., Jakawich, S. K., Wright, R., Chu, C., Sutton, M. A., & Patrick, G. N. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.4427-11.2012 · Cited by 112
Grimm, S., Ott, C., Hörlacher, M., Weber, D., Höhn, A., & Grune, T. (2012) · Biochemical Journal · doi:10.1042/bj20120298 · Cited by 87
Safety of proteasome inhibitors for treatment of multiple myeloma
Schlafer, D., Shah, K. S., Panjic, E. H., & Lonial, S. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1259310 · Cited by 71 · cited 1×
“The use of proteasome inhibitors in cancer treatment is a well-known example of using the proteasome as a therapeutic target (Orlowski and Kuhn, 2008; Schlafer et al., 2017), which raises the question whether intervention in the proteasome system would also be beneficial in other diseases (Njomen and Tepe, 2019).”
BackgroundLin, J.-T., Chang, W.-C., Chen, H.-M., Lai, H.-L., Chen, C.-Y., Tao, M.-H., & Chern, Y. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.01434-12 · Cited by 70
Marquez-Lona, E. M., Torres-Machorro, A. L., Gonzales, F. R., Pillus, L., & Patrick, G. N. (2017) · PLOS ONE · doi:10.1371/journal.pone.0179893 · Cited by 17
Cited by
Erythroid mitochondrial retention triggers myeloid-dependent type I interferon in human SLE
Caielli, S., Cardenas, J., de Jesus, A. A., Baisch, J., Walters, L., Blanck, J. P., Balasubramanian, P., Stagnar, C., Ohouo, M., Hong, S., et al. (2021) · Cell · doi:10.1016/j.cell.2021.07.021 · Cited by 228
Protein synthesis, degradation, and energy metabolism in T cell immunity
Marchingo, J. M., & Cantrell, D. A. (2022) · Cellular & Molecular Immunology · doi:10.1038/s41423-021-00792-8 · Cited by 169
Mechanisms of substrate recognition by the 26S proteasome
Davis, C., Spaller, B. L., & Matouschek, A. (2021) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2020.10.010 · Cited by 66
“Considering the intrinsically disordered regions in some proteasomal subunits play significant regulatory roles through post-translational modification or protein interaction, sequence bias and proteasome architecture may have evolved to maintain proteasome stability and function [57,58].”
BackgroundSubstrate-specific effects of natural genetic variation on proteasome activity
Collins, M. A., Avery, R., & Albert, F. W. (2023) · PLOS Genetics · doi:10.1371/journal.pgen.1010734 · Cited by 11
Substrate-Specific Effects of Natural Genetic Variation on Proteasome Activity
Collins, M. A., Avery, R. R., & Albert, F. W. (2021) · doi:10.1101/2021.11.23.469794 · Cited by 11
Metadata
- Authors
- Kors, S., Geijtenbeek, K., Reits, E., & Schipper-Krom, S.
- Venue
- Frontiers in Molecular Biosciences
- Publisher
- Frontiers Media SA
- Published
- 2019-07-16
- Volume
- 6
- Pages
- 48-48
- ISSN
- 2296-889X (ISSN-L)
- OpenAlex
- W2956624844
- Cited by
- 105
- References
- 27
- FWCI
- 3.94
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.